No Data
Revance Therapeutics Extends Tender Offer Deadline For Merger With Crown Laboratories To December 3, 2024 Amid Ongoing Discussions
Express News | Revance Therapeutics Inc - Ongoing Discussions May Result in Further Delays or Modifications to Merger Agreement
Hyaluronic Acid Market Report 2024, Featuring Profiles of Allergan, Galderma, Revance Therapeutics, Hyaluronic Acid Manufacturing Co. and Fidia Farmaceutici - Forecasts to 2029
Barclays Maintains Revance Therapeutics(RVNC.US) With Hold Rating, Maintains Target Price $7
Barclays Remains a Hold on Revance Therapeutics (RVNC)
Mizuho Securities Maintains Revance Therapeutics(RVNC.US) With Hold Rating
No Data